HRMY Harmony Biosciences Holdings Inc
Price (delayed)
$39.13
Market cap
$2.22B
P/E Ratio
19.76
Dividend/share
N/A
EPS
$1.98
Enterprise value
$2.09B
Harmony Biosciences Holdings, Inc. operates as a pharmaceutical company. The Company focuses on the research, drug development, and treatment for neurologic disorder of sleep-wake state instability. Harmony Biosciences Holdings serves
Highlights
The company's revenue rose by 32% YoY and by 6% QoQ
The gross profit has grown by 29% YoY and by 6% from the previous quarter
Harmony Biosciences Holdings's net income has decreased by 43% YoY and by 16% from the previous quarter
Harmony Biosciences Holdings's EPS has decreased by 41% YoY and by 16% QoQ
Key stats
What are the main financial stats of HRMY
Market
Valuations
Earnings
Shares outstanding
56.83M
Market cap
$2.22B
Enterprise value
$2.09B
Price to earnings (P/E)
19.76
Price to book (P/B)
4.13
Price to sales (P/S)
3.39
EV/EBIT
10.89
EV/EBITDA
9.66
EV/Sales
3.19
Revenue
$656.11M
EBIT
$192.28M
EBITDA
$216.68M
Free cash flow
$212.78M
Per share
Balance sheet
Liquidity
EPS
$1.98
Free cash flow per share
$3.75
Book value per share
$9.48
Revenue per share
$11.55
TBVPS
$12.91
Total assets
$858.38M
Total liabilities
$319.8M
Debt
$186.42M
Equity
$538.58M
Working capital
$311.76M
Debt to equity
0.35
Current ratio
3.13
Quick ratio
2.93
Net debt/EBITDA
-0.6
Margins
Efficiency
Dividend
EBITDA margin
33%
Gross margin
79.4%
Net margin
17.5%
Operating margin
27.1%
Return on assets
14%
Return on equity
23%
Return on invested capital
46.3%
Return on capital employed
27%
Return on sales
29.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HRMY stock price
How has the Harmony Biosciences Holdings stock price performed over time
Intraday
0.57%
1 week
6.07%
1 month
11.99%
1 year
4.29%
YTD
21.15%
QTD
29.7%
Financial performance
How have Harmony Biosciences Holdings's revenue and profit performed over time
Revenue
$656.11M
Gross profit
$521.03M
Operating income
$178.09M
Net income
$114.99M
Gross margin
79.4%
Net margin
17.5%
The net margin has plunged by 56% YoY and by 22% from the previous quarter
Harmony Biosciences Holdings's net income has decreased by 43% YoY and by 16% from the previous quarter
The company's revenue rose by 32% YoY and by 6% QoQ
The gross profit has grown by 29% YoY and by 6% from the previous quarter
Growth
What is Harmony Biosciences Holdings's growth rate over time
Valuation
What is Harmony Biosciences Holdings stock price valuation
P/E
19.76
P/B
4.13
P/S
3.39
EV/EBIT
10.89
EV/EBITDA
9.66
EV/Sales
3.19
Harmony Biosciences Holdings's EPS has decreased by 41% YoY and by 16% QoQ
The stock's price to earnings (P/E) is 36% more than its last 4 quarters average of 14.4
The stock's price to book (P/B) is 61% less than its 5-year quarterly average of 10.4 but 8% more than its last 4 quarters average of 3.8
Harmony Biosciences Holdings's equity has increased by 11% YoY and by 4.5% from the previous quarter
HRMY's P/S is 46% below its 5-year quarterly average of 6.2 but 5% above its last 4 quarters average of 3.2
The company's revenue rose by 32% YoY and by 6% QoQ
Efficiency
How efficient is Harmony Biosciences Holdings business performance
The ROE has plunged by 52% YoY and by 19% from the previous quarter
HRMY's return on assets has dropped by 51% year-on-year and by 19% since the previous quarter
Harmony Biosciences Holdings's return on sales has decreased by 17% QoQ and by 7% YoY
HRMY's return on invested capital is down by 15% since the previous quarter but it is up by 7% year-on-year
Dividends
What is HRMY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HRMY.
Financial health
How did Harmony Biosciences Holdings financials performed over time
HRMY's total assets is 168% greater than its total liabilities
The quick ratio has contracted by 37% YoY
The current ratio has contracted by 36% YoY
The debt is 65% less than the equity
Harmony Biosciences Holdings's equity has increased by 11% YoY and by 4.5% from the previous quarter
The debt to equity has declined by 10% year-on-year and by 5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.